GSK

GSK is a global biopharmaceutical company focused on developing medicines and vaccines, with work spanning research, clinical development, manufacturing and supply. Its areas of innovation include respiratory, immunology and inflammation, oncology, HIV and infectious diseases. The company also provides information about its products, clinical trials and research pipeline, and works with healthcare professionals, research partners and other organisations.

GSK’s acquisition of Affinivax in 2022 strengthened its vaccines portfolio and scientific presence in the Boston area. Affinivax was a clinical-stage biotechnology company developing vaccines using its Multiple Antigen Presenting System (MAPS) platform. Its most advanced candidate at the time, AFX3772, was a 24-valent pneumococcal vaccine in Phase II development, with preparations for Phase III underway. A further, 30-plus-valent candidate was in preclinical development. The MAPS platform combines pathogen-derived polysaccharides and proteins in a single vaccine and was being explored primarily for pneumococcal disease, with potential applications to other infectious disease pathogens. GSK also shares company, investor and responsibility information, and offers career opportunities across research, manufacturing, engineering and commercial functions.